文献速递胸部CTDR

住院免疫功能低下患者SARS-CoV-2突破感染的临床与影像学特征

Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
PubMed 文献 · Korean J Radiol · 2024-03-20

这项回顾性研究分析了2021年6月至2022年12月两家学术医疗中心2218例接种过至少一剂SARS-CoV-2疫苗的住院COVID-19成人患者,比较免疫功能低下与免疫功能正常患者的临床和影像学特征。免疫功能低下患者发生不良临床结局、胸片显示的重度肺炎及典型CT肺炎的风险升高,其中实体器官移植后患者与全部三项结局风险升高相关。

要点

  • 免疫功能低下患者突破感染后重度影像学肺炎(≥25%肺受累)及典型CT肺炎风险更高。
  • 实体器官移植后患者三项结局风险均升高,不良临床结局校正OR为3.12。
  • 活动性实体器官癌与不良临床结局相关,活动性血液系统癌与重度肺炎及典型CT肺炎相关。

核心结论

  • 免疫功能低下COVID-19突破感染患者发生不良临床结局、胸片重度肺炎及典型CT肺炎的风险增加,其中实体器官移植后患者三项结局风险均高于住院免疫功能正常患者。

研究设计与样本

  • 回顾性研究,纳入2021年6月至2022年12月两家学术医疗中心连续收治的接种至少一剂SARS-CoV-2疫苗的住院COVID-19成人患者2218例(平均年龄69.5±16.1岁),比较免疫功能低下患者274例(12.4%)与免疫功能正常患者1944例(87.6%)。

诊断标准与关键数值

  • 重度影像学肺炎定义为肺部受累≥25%;不良临床结局包括院内死亡、机械通气或入住重症监护室;采用多因素logistic回归评估免疫状态对结局的影响。

临床应用与阅片要点

  • 免疫功能低下患者(尤其实体器官移植后)突破感染住院时,阅片需关注肺部受累范围是否≥25%及典型CT肺炎表现,以辅助评估重度肺炎风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the clinical and imaging characteristics of SARS-CoV-2 breakthrough infection in hospitalized immunocompromised patients in comparison with immunocompetent patients.

MATERIALS AND METHODS: This retrospective study analyzed consecutive adult patients hospitalized for COVID-19 who received at least one dose of the SARS-CoV-2 vaccine at two academic medical centers between June 2021 and December 2022. Immunocompromised patients (with active solid organ cancer, active hematologic cancer, active immune-mediated inflammatory disease, status post solid organ transplantation, or acquired immune deficiency syndrome) were compared with immunocompetent patients. Multivariable logistic regression analysis was performed to evaluate the effect of immune status on severe clinical outcomes (in-hospital death, mechanical ventilation, or intensive care unit admission), severe radiologic pneumonia (≥ 25% of lung involvement), and typical CT pneumonia.

RESULTS: Of 2218 patients (mean age, 69.5 ± 16.1 years), 274 (12.4%), and 1944 (87.6%) were immunocompromised an immunocompetent, respectively. Patients with active solid organ cancer and patients status post solid organ transplantation had significantly higher risks for severe clinical outcomes (adjusted odds ratio = 1.58 [95% confidence interval {CI}, 1.01-2.47], P = 0.042; and 3.12 [95% CI, 1.47-6.60], P = 0.003, respectively). Patient status post solid organ transplantation and patients with active hematologic cancer were associated with increased risks for severe pneumonia based on chest radiographs (2.96 [95% CI, 1.54-5.67], P = 0.001; and 2.87 [95% CI, 1.50-5.49], P = 0.001, respectively) and for typical CT pneumonia (9.03 [95% CI, 2.49-32.66], P < 0.001; and 4.18 [95% CI, 1.70-10.25], P = 0.002, respectively).

CONCLUSION: Immunocompromised patients with COVID-19 breakthrough infection showed an increased risk of severe clinical outcome, severe pneumonia based on chest radiographs, and typical CT pneumonia. In particular, patients status post solid organ transplantation was specifically found to be associated with a higher risk of all three outcomes than hospitalized immunocompetent patients.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lee JE, Kim J, Hwang M, et al. Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients. Korean J Radiol. 2024. PMID: 38627873. doi:10.3348/kjr.2023.0992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。